专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07943768B2 Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases 失效
标题翻译：可用作C-C趋化因子（Ccr2b和CcrS）拮抗剂治疗炎性疾病的哌嗪化合物
公开(公告)号：US07943768B2
公开(公告)日：2011-05-17
申请号：US12158248
申请日：2006-12-18
申请人： Justin Fairfield Bower , Peter Wedderburn Kenny , Jeffrey Philip Poyser
发明人： Justin Fairfield Bower , Peter Wedderburn Kenny , Jeffrey Philip Poyser
IPC分类号： C07D239/72 , C07D403/00 , C07D401/00 , C07D413/00 , C07D417/00 , C07D419/00 , C07D405/00 , C07D409/00 , C07D295/00 , C07D411/00 , C07D213/46 , C07D211/60
CPC分类号： C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D407/14 , C07D413/14 , C07D417/14
摘要： A compound of formula (I) P—W—C(═X)-L-Q (I) wherein P is an optionally substituted aryl or heteroaryl group; W is an optionally substituted 6 or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 independently selected from Oxygen and Nitrogen, X is selected from Oxygen, Nitrogen and Sulphur; L is an optional C1-4 linker; and Q is an optionally substituted 4-7 membered aliphatic ring: for use in the treatment of chemokine mediated diseases or disorders.
摘要翻译：式（I）化合物P-W-C（= X）-L-Q（I）其中P是任选取代的芳基或杂芳基; W是任选取代的6或7元脂环，其包含独立选自氧和氮的环原子Y 1和Y 2，X选自氧，氮和硫; L是可选的C1-4连接体; 和Q是任选取代的4-7元脂族环：用于治疗趋化因子介导的疾病或病症。

2. 发明申请

US20080287453A1 Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases 失效
标题翻译：可用作C-C趋化因子（Ccr2b和Ccr5）拮抗剂治疗炎性疾病的哌嗪化合物
公开(公告)号：US20080287453A1
公开(公告)日：2008-11-20
申请号：US12158248
申请日：2006-12-18
申请人： Justin Fairfield Bower , Peter Wedderburn Kenny , Jeffrey Philip Poyser
发明人： Justin Fairfield Bower , Peter Wedderburn Kenny , Jeffrey Philip Poyser
IPC分类号： A61K31/496 , C07D401/06 , A61K31/506 , C07D401/14
CPC分类号： C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D407/14 , C07D413/14 , C07D417/14
摘要： A compound of formula (I) P—W—C(═X)-L-Q (I) wherein P is an optionally substituted aryl or heteroaryl group; W is an optionally substituted 6 or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 independently selected from Oxygen and Nitrogen, X is selected from Oxygen, Nitrogen and Sulphur; L is an optional C1-4 linker; and Q is an optionally substituted 4-7 membered aliphatic ring: for use in the treatment of chemokine mediated diseases or disorders.
摘要翻译：式（I）的化合物<？in-line-formula description =“In-line Formulas”end =“lead”？> PWC（-X）-LQ（I）<？in-line-formula description =“In 其中P是任选取代的芳基或杂芳基; W是任选取代的6或7元脂环，其包含独立地选自氧和氮的环原子Y 1和Y 2，X选自氧，氮和硫 ; L是可选的C 1-4 - 连接基; 和Q是任选取代的4-7元脂族环：用于治疗趋化因子介导的疾病或病症。

3. 发明授权

US07906645B2 Heterocyclic compounds as ccr2b antagonists 失效
标题翻译：杂环化合物作为ccr2b拮抗剂
公开(公告)号：US07906645B2
公开(公告)日：2011-03-15
申请号：US11793606
申请日：2005-12-19
申请人： Justin Fairfield Bower , Jeffrey Philip Poyser , David Waterson
发明人： Justin Fairfield Bower , Jeffrey Philip Poyser , David Waterson
IPC分类号： C07D241/02 , A61K31/495
CPC分类号： C07D295/195 , C07D207/09 , C07D211/26 , C07D211/46 , C07D211/60 , C07D265/30 , C07D295/02 , C07D295/215 , C07D401/06 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06
摘要： Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.
摘要翻译：式（I）化合物Q-L-W-C（= X）-Z-P其中Q是式-N（R1）（R2）的胺; L是烷基或杂环基 - 烷基接头; W是分别连接到基团L和C（X）的环原子Y1和Y2的6或7元脂肪环，Y1和Y2独立地选自N和C; X是O，N，N-CN或S; Z为NR3; P是任选取代的单环或双环芳基或杂芳基; 和其药学上可接受的盐或溶剂化物，可用于治疗C-C趋化因子介导的病症。

4. 发明申请

US20120264762A1 Heterocyclic Compounds as CCR2 Antagonists 审中-公开
标题翻译：杂环化合物作为CCR2拮抗剂
公开(公告)号：US20120264762A1
公开(公告)日：2012-10-18
申请号：US13490765
申请日：2012-06-07
申请人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
发明人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
IPC分类号： A61K31/496 , A61P1/00 , A61P11/00 , A61P9/10 , A61K31/506 , A61P29/00
CPC分类号： C07D295/195 , C07D207/09 , C07D211/26 , C07D211/46 , C07D211/60 , C07D265/30 , C07D295/02 , C07D295/215 , C07D401/06 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06
摘要： Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.
摘要翻译：式（I）化合物Q-L-W-C（= X）-Z-P其中Q是式-N（R1）（R2）的胺; L是烷基或杂环基 - 烷基接头; W是分别连接到基团L和C（X）的环原子Y1和Y2的6或7元脂肪环，Y1和Y2独立地选自N和C; X是O，N，N-CN或S; Z为NR3; P是任选取代的单环或双环芳基或杂芳基; 和其药学上可接受的盐或溶剂化物，可用于治疗C-C趋化因子介导的病症。

5. 发明申请

US20110136820A1 Heterocyclic Compounds as CCR2 Antagonists 审中-公开
标题翻译：杂环化合物作为CCR2拮抗剂
公开(公告)号：US20110136820A1
公开(公告)日：2011-06-09
申请号：US13018783
申请日：2011-02-01
申请人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
发明人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
IPC分类号： A61K31/496 , A61K31/506 , A61P11/00 , A61P11/06 , A61P29/00 , A61P19/10 , A61P19/02
CPC分类号： C07D295/195 , C07D207/09 , C07D211/26 , C07D211/46 , C07D211/60 , C07D265/30 , C07D295/02 , C07D295/215 , C07D401/06 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06
摘要： Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.
摘要翻译：式（I）化合物Q-L-W-C（= X）-Z-P其中Q是式-N（R1）（R2）的胺; L是烷基或杂环基 - 烷基接头; W是分别连接到基团L和C（X）的环原子Y1和Y2的6或7元脂肪环，Y1和Y2独立地选自N和C; X是O，N，N-CN或S; Z为NR3; P是任选取代的单环或双环芳基或杂芳基; 和其药学上可接受的盐或溶剂化物，可用于治疗C-C趋化因子介导的病症。

6. 发明申请

US20090099156A1 Heterocyclic Compounds as Ccr2b antagonists 失效
标题翻译：杂环化合物作为Ccr2b拮抗剂
公开(公告)号：US20090099156A1
公开(公告)日：2009-04-16
申请号：US11793606
申请日：2005-12-19
申请人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
发明人： Justin Fairfield Bower , Jeffrey Philip Poyser , Paul Turner , David Waterson , Jon Winter
IPC分类号： A61K31/551 , C07D401/06 , A61K31/5377 , A61P1/00 , A61P35/00 , A61P19/02 , C07D413/06 , A61K31/496
CPC分类号： C07D295/195 , C07D207/09 , C07D211/26 , C07D211/46 , C07D211/60 , C07D265/30 , C07D295/02 , C07D295/215 , C07D401/06 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06
摘要： Compounds of formula (I) Q-L-W—C(═X)-Z-P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.
摘要翻译：式（I）化合物Q-L-W-C（-X）-Z-P其中Q是式-N（R1）（R2）的胺; L是烷基或杂环基 - 烷基接头; W是分别连接到基团L和C（X）的环原子Y1和Y2的6或7元脂肪环，Y1和Y2独立地选自N和C; X是O，N，N-CN或S; Z为NR3; P是任选取代的单环或双环芳基或杂芳基; 和其药学上可接受的盐或溶剂化物，可用于治疗C-C趋化因子介导的病症。

7. 发明授权

US07572826B2 Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 失效
标题翻译：噻吩 - 甲酰胺衍生物及其作为IKK-2酶抑制剂的用途
公开(公告)号：US07572826B2
公开(公告)日：2009-08-11
申请号：US10542326
申请日：2004-01-13
申请人： Alan Wellington Faull , Craig Johnstone , Andrew David Morley , Jeffrey Philip Poyser
发明人： Alan Wellington Faull , Craig Johnstone , Andrew David Morley , Jeffrey Philip Poyser
IPC分类号： A61K31/381 , C07D333/36
CPC分类号： C07D409/12 , C07D333/38 , C07D333/44 , C07D413/12
摘要： The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明涉及式（I）的噻吩甲酰胺，其中A，R 1，R 2，R 3，R 4，R 5和X如说明书中所定义，其制备中使用的方法和中间体，含有它们的药物组合物及其在治疗中的用途。

8. 发明申请

US20100029754A1 THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 审中-公开
标题翻译：三苯甲酰胺衍生物及其作为酶的抑制剂IKK-2
公开(公告)号：US20100029754A1
公开(公告)日：2010-02-04
申请号：US12537532
申请日：2009-08-07
申请人： Alan Wellington Faull , Craig Johnstone , Andrew David Morley , Jeffrey Philip Poyser
发明人： Alan Wellington Faull , Craig Johnstone , Andrew David Morley , Jeffrey Philip Poyser
IPC分类号： A61K31/381 , C07D333/38 , A61P29/00 , A61P11/00
CPC分类号： C07D409/12 , C07D333/38 , C07D333/44 , C07D413/12
摘要： The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明涉及式（I）的噻吩甲酰胺，其中A，R 1，R 2，R 3，R 4，R 5和X如说明书中所定义，其制备中使用的方法和中间体，含有它们的药物组合物及其在治疗中的用途。

9. 发明授权

US07001904B1 Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases 失效
标题翻译：胍衍生物喹唑啉和喹啉用于治疗自身免疫性疾病
公开(公告)号：US07001904B1
公开(公告)日：2006-02-21
申请号：US10311587
申请日：2001-06-19
申请人： Jeffrey Philip Poyser
发明人： Jeffrey Philip Poyser
IPC分类号： C07D403/12 , C07D413/12 , A61K31/505
CPC分类号： C07D401/12 , C07D239/94 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14
摘要： The invention concerns quinazoline and quinoline derivatives of Formula (I) wherein Q1 includes a quinazoline or quinoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2, R3 and R5 is hydrogen or (1-6C)alkyl, provides that one of the parts of groups R2 and R4 together, R3 and R4 together and R5 and R4 together forms a bond; R6 is an optionally substituted group selected from (2-6C) alkenyl, (2-6C) alkynyl, (3-7C)cycloalkyl and (3-7C) cycloalkenyl, or R6 is a substituted (1-6C) alkyl group; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
摘要翻译：本发明涉及式（I）的喹唑啉和喹啉衍生物，其中Q 1包括任选被诸如卤代，三氟甲基和氰基的基团取代的喹唑啉或喹啉，或下式的基团：其中X 1包括直接键，O和Q 3包括芳基，芳基 - （ 1-6C）烷基，杂环基和杂环基 - （1-6C）烷基; R 2，R 3和R 5各自为氢或（1-6C）烷基，提供基团R的一部分 R 2和R 4一起，R 3和R 4一起和R 5，和R 4一起形成键; R 6是选自（2-6C）烯基，（2-6C）炔基，（3-7C）环烷基和（3-7C）环烯基中的任选取代的基团，或R 6 取代的（1-6C）烷基; 并且Q 2包括芳基和芳基 - （1-3C）烷基或其药学上可接受的盐; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗温血动物中的T细胞介导的疾病或医学病症的药物中的用途。

10. 发明授权

US06806274B1 Quinazoline derivatives 失效
标题翻译：喹唑啉衍生物
公开(公告)号：US06806274B1
公开(公告)日：2004-10-19
申请号：US10019945
申请日：2002-01-07
申请人： Graham C Crawley , Laurent F A Hennequin , Darren McKerrecher , Patrick Ple , Jeffrey Philip Poyser , Christine M P Lambert
发明人： Graham C Crawley , Laurent F A Hennequin , Darren McKerrecher , Patrick Ple , Jeffrey Philip Poyser , Christine M P Lambert
IPC分类号： A61K31517
CPC分类号： C07D231/12 , C07D215/54 , C07D233/56 , C07D239/94 , C07D249/08 , C07D401/12 , C07D403/12 , C07D417/12 , C07D487/04
摘要： The invention concerns quinazoline derivatives of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2 and R3 is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
摘要翻译：本发明涉及式（I）的喹唑啉衍生物，其中Q 1包括任选被诸如卤代，三氟甲基和氰基的基团取代的喹唑啉环，或下式：Q 3 -X 1 - 的基团，其中 X 1包括直接键，O和Q 3包括芳基，芳基 - （1-6C）烷基，杂环基和杂环基 - （1-6C）烷基; R 2和R 3各自为氢或（1-6C）烷基; Z包括O，S和NH; 和Q 2包括芳基和芳基 - （1-3C）烷基或其药学上可接受的盐; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗温血动物中的T细胞介导的疾病或医学病症的药物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式